Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Aarti, Adcirca, Aetna, agonist, Agri, AIA, AMP, AOCL, arbitration, arose, Arzneimittel, ASC, assimilate, Assimilation, ASU, Augusta, Avid, Baker, Barnett, Bipartisan, BIVIP, BIVIVP, bolster, BPCI, broiler, chicken, Christensen, compatible, compliant, conspiracy, contest, corrective, CureVac, curtailment, Daniel, deploy, disproportionate, Dodge, Dual, Eagle, error, exploitation, exploring, Florida, Fort, founder, fraud, fundamentally, Galliprant, gather, Georgia, GILTI, hardware, hookworm, Hurricane, installment, interference, Iowa, Johna, Joshua, KeyBioscience, lanabecestat, Ltda, merger, metabolic, Microsoft, middle, Minnesota, Mississippi, misused, MSP, narrative, Nektar, Nipro, Norton, obsolescence, owed, PCAOB, pertinent, Pharm, plaintiff, provisional, Pusey, Quimica, Rabvac, Radiopharmaceutical, rbST, reclassification, refile, regime, remeasurement, remeasuring, rendered, Restated, Resubmitted, retention, retroactive, RNActive, roundworm, rulemaking, scheme, Shah, Shaw, shut, Skovronsky, Smiley, Stada, Strafford, stranded, Streck, succeeded, superseded, surfaced, tapeworm, temporarily, Toll, unsealed, Verzenio, VerzenioTM, Washington, whipworm, withholding, XR
Removed:
Abbott, absence, Allergan, amendment, API, applicator, apportioned, attention, awarded, Barton, bound, chairman, choose, close, Crowe, Cuxhaven, Derica, evacetrapib, extra, FASB, finance, Fionnuala, granting, headquartered, Immunocore, indemnify, issue, Ixekizumab, John, leader, Lechleiter, lodged, Lohmann, Louisiana, Necitumumab, neutralizing, operational, opposition, PCI, peglispro, Peterson, ratio, remained, remitted, repaid, repatriated, Rice, Saavedra, Sandoz, SE, Shionogi, subsequently, supporting, taxed, topical, underarm, variability, Walsh
Filing tables
Filing exhibits
- 10-K Annual report
- 10.2 Eli Lilly and Company Performance Award (for Executive Officers)
- 10.3 Exhibit 10.3
- 12 Statement Re: Computation of Ratio of Earnings (Loss) to Fixed Charges
- 21 List of Subsidiaries and Affiliates
- 23 Consent of Independent Registered Public Accounting Firm
- 31.1 Rule 13A-14(A) Certification of David A. Ricks, President & Chief Executive Offi
- 31.2 Rule 13A-14(A) Certification of Derica W. Rice, Executive Vice President, Global
- 32 Section 1350 Certification
- Download Excel data file
- View Excel data file
Related press release
Associated LLY transcripts
LLY similar filings
Filing view
External links
Exhibit 23
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Form S-3ASR Nos. 333-209627; and Form S-8 Nos. 333-104057 and 333-172422) of Eli Lilly and Company and subsidiaries and in the related Prospectus of our reports dated February 20, 2018, with respect to the consolidated financial statements of Eli Lilly and Company and subsidiaries, and the effectiveness of internal control over financial reporting of Eli Lilly and Company and subsidiaries, included in this Annual Report (10-K) for the year ended December 31, 2017.
/s/ Ernst and Young LLP
Indianapolis, Indiana
February 20, 2018